FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2563490717> ?p ?o ?g. }

• W2563490717 endingPage "37834" @default.
• W2563490717 startingPage "37826" @default.
• W2563490717 abstract "// Wenhua Li 1,2 , Xiaoying Zhao 1,2 , Huijie Wang 1,2 , Xin Liu 1,2 , Xinmin Zhao 1,2 , Mingzhu Huang 1,2 , Lixin Qiu 1,2 , Wen Zhang 1,2 , Zhiyu Chen 1,2 , Weijian Guo 1,2 , Jin Li 1,2,* and Xiaodong Zhu 1,2,* 1 Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China 2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China * Xiaodong Zhu and Jin Li contributed equally to this work Correspondence to: Xiaodong Zhu, email: // Jin Li, email: // Keywords : gastric carcinoma; UFT; chemotherapy; maintenance treatment Received : October 24, 2016 Accepted : December 01, 2016 Published : December 12, 2016 Abstract Background: Maintenance therapy proves to be effective in advanced lung and breast cancer after initial chemotherapy. The purpose of this phase II study was to evaluate the efficacy and safety of Uracil and Tegafur (UFT) maintenance in metastatic gastric cancer patients following the first-line fluorouracil-based chemotherapy. Methods: Metastatic gastric cancer patients with stable disease or a better response after the completion of first-line chemotherapy were randomized to oral UFT (360mg/m2 × 2 weeks) every 3 weeks until disease progression/intolerable toxicity or to observation (OBS). The primary endpoint was progression-free survival (PFS); the secondary endpoints were overall survival (OS) and safety.  Results: The trial was closed after the interim analysis of the 58 enrolled (120 planned) patients. Median PFS was not improved in the UFT group compared with the OBS group (3.2 months versus 3.6 months, P = 0.752), as well as the median OS (14.2 months for both, P = 0.983). However, subgroup analysis showed that low baseline hemoglobin (< 120 g/L) was associated with poorer PFS with maintenance therapy ( P = 0.032), while the normal hemoglobin patients benefit from the UFT treatment ( P = 0.008). Grade 3 to 4 toxicities in the UFT group were anemia (3.4%), thrombocytopenia (3.4%) and diarrhea (6.9%). Conclusions: This trial did not show superiority of UFT maintenance in non-selected patients responding to fluorouracil-based first-line chemotherapy. The normal hemoglobin level at baseline is a predictive biomarker for favorable patient subsets from the maintenance treatment." @default.
• W2563490717 created "2017-01-06" @default.
• W2563490717 creator A5001162052 @default.
• W2563490717 creator A5007875050 @default.
• W2563490717 creator A5013312078 @default.
• W2563490717 creator A5020353950 @default.
• W2563490717 creator A5021687717 @default.
• W2563490717 creator A5052168680 @default.
• W2563490717 creator A5053048373 @default.
• W2563490717 creator A5058433699 @default.
• W2563490717 creator A5065490078 @default.
• W2563490717 creator A5078949281 @default.
• W2563490717 creator A5084985894 @default.
• W2563490717 creator A5085594231 @default.
• W2563490717 date "2016-12-12" @default.
• W2563490717 modified "2023-09-26" @default.
• W2563490717 title "Maintenance treatment of Uracil and Tegafur (UFT) in responders following first-line fluorouracil-based chemotherapy in metastatic gastric cancer: a randomized phase II study" @default.
• W2563490717 cites W1522051322 @default.
• W2563490717 cites W1985210944 @default.
• W2563490717 cites W1991343765 @default.
• W2563490717 cites W2005244154 @default.
• W2563490717 cites W2037166664 @default.
• W2563490717 cites W2040446578 @default.
• W2563490717 cites W2044970916 @default.
• W2563490717 cites W2067509607 @default.
• W2563490717 cites W2075689325 @default.
• W2563490717 cites W2077902459 @default.
• W2563490717 cites W2086112837 @default.
• W2563490717 cites W2100912832 @default.
• W2563490717 cites W2103359811 @default.
• W2563490717 cites W2116419063 @default.
• W2563490717 cites W2124451268 @default.
• W2563490717 cites W2128328462 @default.
• W2563490717 cites W2131988196 @default.
• W2563490717 cites W2139675556 @default.
• W2563490717 cites W2142751306 @default.
• W2563490717 cites W2152362765 @default.
• W2563490717 cites W2155167083 @default.
• W2563490717 cites W2164411042 @default.
• W2563490717 cites W2166127437 @default.
• W2563490717 cites W2168600267 @default.
• W2563490717 cites W2169961966 @default.
• W2563490717 cites W2219978888 @default.
• W2563490717 cites W2327116942 @default.
• W2563490717 cites W23971197 @default.
• W2563490717 cites W2404010296 @default.
• W2563490717 cites W2430041197 @default.
• W2563490717 cites W42171688 @default.
• W2563490717 doi "https://doi.org/10.18632/oncotarget.13922" @default.
• W2563490717 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5514953" @default.
• W2563490717 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27980221" @default.
• W2563490717 hasPublicationYear "2016" @default.
• W2563490717 type Work @default.
• W2563490717 sameAs 2563490717 @default.
• W2563490717 citedByCount "12" @default.
• W2563490717 countsByYear W25634907172018 @default.
• W2563490717 countsByYear W25634907172019 @default.
• W2563490717 countsByYear W25634907172020 @default.
• W2563490717 countsByYear W25634907172021 @default.
• W2563490717 countsByYear W25634907172023 @default.
• W2563490717 crossrefType "journal-article" @default.
• W2563490717 hasAuthorship W2563490717A5001162052 @default.
• W2563490717 hasAuthorship W2563490717A5007875050 @default.
• W2563490717 hasAuthorship W2563490717A5013312078 @default.
• W2563490717 hasAuthorship W2563490717A5020353950 @default.
• W2563490717 hasAuthorship W2563490717A5021687717 @default.
• W2563490717 hasAuthorship W2563490717A5052168680 @default.
• W2563490717 hasAuthorship W2563490717A5053048373 @default.
• W2563490717 hasAuthorship W2563490717A5058433699 @default.
• W2563490717 hasAuthorship W2563490717A5065490078 @default.
• W2563490717 hasAuthorship W2563490717A5078949281 @default.
• W2563490717 hasAuthorship W2563490717A5084985894 @default.
• W2563490717 hasAuthorship W2563490717A5085594231 @default.
• W2563490717 hasBestOaLocation W25634907171 @default.
• W2563490717 hasConcept C121608353 @default.
• W2563490717 hasConcept C126322002 @default.
• W2563490717 hasConcept C141071460 @default.
• W2563490717 hasConcept C143998085 @default.
• W2563490717 hasConcept C168563851 @default.
• W2563490717 hasConcept C203092338 @default.
• W2563490717 hasConcept C207103383 @default.
• W2563490717 hasConcept C2776694085 @default.
• W2563490717 hasConcept C2777299880 @default.
• W2563490717 hasConcept C2780456651 @default.
• W2563490717 hasConcept C2780739268 @default.
• W2563490717 hasConcept C44249647 @default.
• W2563490717 hasConcept C61943457 @default.
• W2563490717 hasConcept C71924100 @default.
• W2563490717 hasConcept C90924648 @default.
• W2563490717 hasConceptScore W2563490717C121608353 @default.
• W2563490717 hasConceptScore W2563490717C126322002 @default.
• W2563490717 hasConceptScore W2563490717C141071460 @default.
• W2563490717 hasConceptScore W2563490717C143998085 @default.
• W2563490717 hasConceptScore W2563490717C168563851 @default.
• W2563490717 hasConceptScore W2563490717C203092338 @default.
• W2563490717 hasConceptScore W2563490717C207103383 @default.
• W2563490717 hasConceptScore W2563490717C2776694085 @default.
• W2563490717 hasConceptScore W2563490717C2777299880 @default.

• next